June 25, 2020 / 6:03 AM / 8 days ago

BRIEF-Moberg Pharma Meets Primary Endpoint In The European Phase 3 Study

June 25 (Reuters) - Moberg Pharma AB (publ):

* MOBERG PHARMA MEETS PRIMARY ENDPOINT IN THE EUROPEAN PHASE 3 STUDY

* ANNOUNCES THAT MOB-015 (TOPICAL TERBINAFINE) MET PRIMARY ENDPOINT IN EUROPEAN PHASE 3 STUDY INCLUDING 452 ONYCHOMYCOSIS PATIENTS, SHOWING NON-INFERIORITY VERSUS TOPICAL CICLOPIROX

* MOB-015 WAS GENERALLY WELL TOLERATED Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below